WIRB News and Events

News

The WIRB-Copernicus Group Partners with Mytrus, Inc. to Deliver Revolutionary, Interactive Electronic Informed Consent Solution
Companies Announce Partnership to Improve the Quality and Efficiency of Clinical Trials at the CenterWatch Forum on Optimizing Clinical Research Performance in Boston, MA,
Princeton, NJ (May 20, 2013): The WIRB-Copernicus Group, the world’s largest provider of regulatory and ethical review services for human research, announced today that it has partnered with Mytrus, Inc., a pioneer in "virtual clinical trials" and technologies that improve clinical trial efficiency, to deliver a unique electronic informed consent solution that will help to streamline and enrich the clinical research process. According to the terms of the partnership, The WIRB-Copernicus Group will be Mytrus’ exclusive independent Institutional Review Board (IRB) partner, providing Mytrus’ interactive e-consent as part of its comprehensive ethical oversight solution. To continue reading the press release, please click here.
CWWeekly’s semi-monthly company profile feature
CWWeekly’s semi-monthly company profile feature, Insider Insights, interviews executives of companies and organizations in the clinical trials space. Writer Ronald Rosenberg sat down with Dawn Pope, chief operating officer at Copernicus Group IRB. Read the full article on page 6 of CenterWatch Weekly.
New Streamlined Policy for Unexpected Consent Translations Needs
WIRB has established the following new policy regarding the use a short form consent process to enroll subjects who do not speak English. This policy is limited to the situation when both of the following are true:
- A full-length version of the consent form in a language understandable to the subject is not available, and
- It is in the subject’s best medical interest to be enrolled in the research before a translated consent form can be obtained.
The short form will follow the OHRP template short form , and the subject will have to be reconsented within 30 days with a WIRB-approved consent form in a language understandable to the subject.

Each of the following steps must be followed:
1. The Principal Investigator is to insert study specific information, including title of study, principal investigator, and contact information into the OHRP template short form.
2. The subject must be given a copy of the short form in the language understandable to him/her to read;
3. A translator/interpreter must orally present the entire IRB-approved English ICF;
4. The consent process must be witnessed by an individual who is fluent in both English and the subject’s language;
5. The English ICF must be signed by the investigator and the witness;
6. The short form must be signed by the subject, investigator, and witness;
7. The subject must be given signed copies of the English ICF and short form;
8. The original signed English ICF and the original signed short form should be retained in the subject's research record and medical record, if appropriate; AND
9. The PI will then obtain a fully translated version of the consent form at the earliest opportunity. The subject would then be re-consented using the translated consent form within 30 days.
March 2013 Documentation Changes
As part of WIRB’s continuing efforts to streamline its processes and improve its turnaround time, we have recently made the following changes:
- WIRB has begun an effort to synchronize the expiration dates of all study sites participating in a protocol. Please note that the expiration date of your study may be altered, and that the schedule for completing your Continuing Review Report forms may also be altered to align with the new expiration date.
- The Board has stopped requiring more than one continuing review report form per approval period; you will only receive a Continuing Review Report Form just prior to the scheduled renewal review of the research. As a result, you may notice a change to the “Site Status Reporting” field section of your Certificate of Approval. In the future, the Continuing Review frequency cited on the Certificate will always match the Site Status Reporting frequency cited.
- Each panel’s roster is now provided in a single document. Rather than receiving a roster listing only the members and alternates of the panel the research is assigned to, the roster will list all members of all panels.
- We have discontinued the practice of applying signatures to the Certificate of Approval. Federal regulations do not require a signature on the notification of IRB actions.
- We have restructured the panels. The research for panels 6, 7, 8, 11, 12, 13, and 14 has been distributed to panels 1-5, which now meet twice a week. As a result, the panel number on your Certificate of Approval may reflect a new panel assignment. If your research has been assigned to a new panel, the terms of your study’s approval are unchanged.
These improvements are strengthened by our commitment to provide you with the quality and service you deserve, and to reaffirm WIRB as the industry’s gold-standard. Should you have any questions, please contact us at 1-800-562-4789.

As always, we thank you for your continued business and look forward to serving you in the future.
2013 Fee Schedule Changes and Improvement Updates
At WIRB, it is our goal to provide you with the most efficient, streamlined platform for ethical review. You should come to expect that we will consistently deliver the best possible service and the highest level of quality to you, our client. To further this goal, WIRB has significantly invested in people, processes and technologies that will enable us to better serve you.

First, we have installed a strong leadership team comprised of industry experts and tasked them with optimizing the elements of the review process to eliminate inefficiencies, improve quality, and reduce turn-around time.

Next, we have developed a Consulting Division which aligns top legal, ethical, medical and regulatory experts to provide you with a comprehensive suite of consulting services including IRB assessment, efficiency and effectiveness improvements, AAHRPP accreditation support, FDA audit preparation and readiness, and more.

Last, in response to expressed client need, we have invested in the development of WIRB Connexus, a technology platform that will dramatically improve the IRB submission process. WIRB Connexus is an award-winning e-documentation management system that will provide you with increased transparency, the ability to track submissions and access documents, and access to WIRB support professionals via on-line chat.

These improvements are strengthened by our commitment to provide you with the quality and service you deserve, and to reaffirm WIRB as the industry’s gold-standard. Should you have any questions, please contact us at 1-800-562-4789.

As always, we thank you for your continued business and look forward to serving you in the future.
MAGI Clinical Research Conference - 2013 East
MAGI Clinical Research Conference - 2013 East May 5-8 th, 2013 Westin Copley Place, Boston, MA WIRB Events: Master Class for IRB Professionals - REGISTER NOW! Pre-Conference Workshop: Sunday, May 5 th (9:30am-5:00pm) Presented by: Jeffrey Cooper, MD, MMM, Vice President of Global Consulting, The WIRB-Copernicus Group, R. Bert Wilkins, JD, MHA, CIP, Executive IRB Chair, The WIRB-Copernicus Group, Troy Brinkman, JD, MA, CIP, Manager of Consulting Services, The WIRB-Copernicus Group Recent Developments in Human Subjects Protection Regulation Main Program Session: Monday, May 6 th (10:30am - 11:15am) Presented by: David Forster, JD, MA, CIP, Chief Compliance Officer, The WIRB-Copernicus Group Transforming Ethical Review: The Formation of The WIRB-Copernicus Group Breakfast at the Sheraton Copley Place Hotel: Tuesday, May 7 th (7:00-8:30am) Hosted by: Donald A. Deieso, PhD, Executive Chairman, The WIRB-Copernicus Group Clinical Research Around the World Main Program Session: Wednesday, May 8 th (8:00am-12:00pm) Presented by: R. Bert Wilkins, JD, MHA, CIP, Executive IRB Chair, The WIRB-Copernicus Group
CenterWatch Clinical Research Conference – 2013 East
CenterWatch Clinical Research Conference 2013 East May 19-21 st, 2013 Boston Marriott Copley Place, Boston, MA Anticipating a Shifting Landscape for Local Central IRBs and Ethical Review Committees Main Program Session, Monday, May 20 th (4:15-4:40pm) Presented by: Stuart Horowitz, PhD, MBA, President of Global Consulting, The WIRB-Copernicus Group Transforming Ethical Review: The Formation of The WIRB-Copernicus Group Luncheon at the Marriott Copley Place Hotel, Tuesday, May 21 st (12:30-1:30pm) Hosted by: Donald A. Deieso, PhD, Executive Chairman, The WIRB-Copernicus Group Roll-ups and Mergers in the Clinical Research Sector Co-located Session, Tuesday, May 21 st (1:30-2:30pm) Presented by: Donald A. Deieso, PhD, Executive Chairman, The WIRB-Copernicus Group
ASCO Annual Meeting
ASCO Annual Meeting May 31-June 4 th, 2013 McCormick Place, Chicago, IL WIRB Events: Exhibit Hall: The WIRB-Copernicus Group, Booth #12127
DIA 49th Annual Meeting
DIA 49th Annual Meeting June 23-27 th, 2013 Boston Convention and Exhibition Center, Boston, MA WIRB Events: Exhibit Hall: The WIRB-Copernicus Group, Booth #1234 Transforming Ethical Review: The Formation of The WIRB-Copernicus Group Dinner Reception at the New England Aquarium, Tuesday, June 25 th (6:00-10:00pm) Hosted by: Donald A. Deieso, PhD, Executive Chairman, The WIRB-Copernicus Group Transforming Ethical Review: The Formation of The WIRB-Copernicus Group Western IRB (WIRB) and Copernicus Group IRB (CGIRB), the nation's leading independent institutional review boards, have come together with IRBNet, the top software application supporting institutional IRBs, to form The WIRB-Copernicus Group. The WIRB-Copernicus Group is the world's largest provider of regulatory and ethical review services for human research. It is our mission to meet the highest standards of ethics and science, and to ensure the safety and welfare of subjects worldwide. To learn more about The WIRB-Copernicus Group, please attend one of our upcoming hosted events, during which we will discuss our transformational approach to ethical review: Tuesday, May 7 th(7:00-8:30am): Breakfast at the Sheraton Copley Place Hotel, Boston, MA Tuesday, May 21 st (1:30-2:30pm): Luncheon at the Marriott Copley Place Hotel, Boston, MA Tuesday, June 25 th (6:00-10:00pm): Dinner at the New England Aquarium, Boston, MA

Oct. 4-5th, Seattle Waterfront - 2012 WIRB Annual Knowledge Summit
The theme of our 2012 Knowledge Summit is “The Risk Benefit Balance, Decisions, Mistakes and Ethics”. We have assembled a group of speakers who will address the core tenets that drive good organizational behavior and decision making, key factors in achieving IRB quality goals. This year’s event includes ample opportunity for networking with your peers from among our extraordinary client base.

Agenda
Speakers
Logistics
Registration
Eight WIRB staff had the pleasure of attending the Drug Information Association (DIA) 2012 Annual Meeting in Philadelphia June 25-28, 2012
The Drug Information Association (DIA) 2012 Annual Meeting is the largest multidisciplinary event for professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products.

DIA featured 500 different exhibitors and 8,000 attendees with WIRB being the largest IRB exhibit. Linda Morrison, Sherry Felchlin, Carrie Fisher, Cindy Gates, Ian Zhao, Angela Regensburg, Monika Roberts and Vanessa Wasman all attended DIA , staffed the exhibit and met with many of WIRB’s current and prospective clientele. WIRB staff also had the pleasure in meeting and spending time with key staff from our sister company Copernicus Group Independent Review Board (CGIRB).

In addition to the exhibit hall, DIA offered nearly 300 different session programs with various learning objectives such as clinical operations, professional development, global regulatory, public policy and health care compliance regulatory law. Cindy Gates gave a presentation on the new U.S. regulations and guidance for the conduct of clinical trials. WIRB also hosted a client reception at the Ritz Carlton on Tuesday, June 26 and had the opportunity to network with key players in the IRB industry.

Congratulations to WIRB and their success at the DIA Annual Meeting!
On March 4, 2012, Dateline NBC aired a story regarding the submission of a fake clinical protocol to three independent IRBs as part of a sting operation.
WIRB refused the review because our internal processes identified the submission as having substantial ethical and regulatory deficiencies. As mentioned in the story, WIRB notified the FDA because WIRB is committed to protecting human subjects who participate in research, and felt that regulatory authorities should be aware of activities that could undermine the safety and integrity of medical research. WIRB is the long standing industry leader in ethical review and maintains a very rigorous process of screening all submissions for IRB review. WIRB’s clients receive exceptional value when compared to other independent IRBs through WIRB’s investment in compliance and high standards of ethical review

If you have any questions, please contact Monika Roberts, Manager, Executive Office of WIRB, at 360-252-2564.
Arsenal Capital Partners and Western Institutional Review Board (WIRB) Announce the Acquisition of WIRB and the Appointment of Leading Clinical Research Experts as Advisors

WIRB Contact
Monika Roberts
360-252-2564
mroberts@wirb.com

March 1, 2012

Arsenal Capital Partners and Western Institutional Review Board (WIRB) Announce the Acquisition of WIRB and the Appointment of Leading Clinical Research Experts as Advisors

Olympia, WA, February 29, 2012 – Western Institutional Review Board (WIRB), a privately held provider of information-based services which play an integral role in the clinical trial process for new drugs and medical devices, announced that the company has been acquired by Arsenal Capital Partners, a leading New York-based private equity firm that invests in middle market healthcare, specialty industrial, and financial services companies.

WIRB, founded in 1968 by Dr. Angela Bowen, is the leading provider of independent institutional review board (IRB), biosafety and other human protection services in the world. IRBs, which are mandated by federal and international regulations, review and approve the handling of ethical issues in research protocols before research involving human subjects can begin. WIRB pioneered the concept of an independent IRB and is currently recognized as the “gold standard” in the industry. The company has offices in the US and Canada and provides review services to research institutions, CROs and major sponsors in all 50 states and in more than 60 countries around the world.

“We are excited about our choice of Arsenal Capital as our partners in creating the next chapter of our evolution. We were impressed with Arsenal’s expertise, capabilities, and commitment to our company’s growth in the U.S. and globally. This is an extraordinarily positive development for our employees, our clients, and for the human subjects we protect,” said Dudley Slater, CEO of WIRB.

Dr. Donald A. Deieso, Operating Partner in Arsenal’s Healthcare Group will become Executive Chairman of WIRB. Dr. Deieso commented, “The globalization of clinical research has created a number of new challenges for protecting human subjects. WIRB will draw upon its longstanding knowledge of regulations and ethical practices to address these exciting challenges.”

Concurrent with the transaction, WIRB has appointed several nationally recognized experts in clinical research and bioethics as Advisors to WIRB. Their addition is expected to strengthen the company’s IRB capabilities and further the company’s planned growth. The new advisors include:

Dr. Jim Bannon – Executive Chair, IndiPharm and Former Group President, Late Stage Development Services, Covance

Dr. Art Caplan – Director, Center for Bioethics, University of Pennsylvania and author and commentator on matters related to human subject protection

Dr. Scott Hayworth – President & CEO, Mount Kisco Medical Group and Former Chair of the American Medical Group Association (AMGA)

Dr. Per Peterson – Former Chairman of Pharmaceutical R&D (PRD), at Johnson and Johnson

Dr. Jim Rothman – Chair, Cell Biology Department at Yale Medical School, and Former Chief Science Officer, GE Healthcare and Vice-Chairman, Sloan-Kettering Institute

David Forster, Chief Compliance Officer at WIRB commented, “We look forward to working with Arsenal and the outstanding group of advisors that have joined us. These individuals will enrich our company with their deep understanding of bioethics, clinical research, investigator perspectives, and institutional requirements. This investment and the addition of such outstanding advisors will continue the legacy of leadership at WIRB.”

About Western Institutional Review Board

WIRB was founded in 1968 and is the leading provider of independent IRB, biosafety and other human protection services to the research institutions, CROs and major sponsors. The company has offices in the US and Canada and provides review services in all 50 states and in more than 60 countries around the world. For additional information on WIRB, please visit www.wirb.com.

About Arsenal Capital Partners

Arsenal Capital Partners is a leading New York-based private equity firm that invests in middle market specialty industrial, healthcare and financial services companies. Arsenal makes investments in sectors where the firm has significant prior knowledge and experience. Arsenal targets businesses that have the potential for further value creation by working closely with management to accelerate growth and leverage the firm’s operational improvement capabilities. Arsenal currently has $800 million of committed equity capital. For additional information on Arsenal Capital Partners, please visit www.arsenalcapital.com.

###

The Office for Human Research Protections (OHRP) is seeking nominations of qualified candidates for appointment to the Secretary’s Advisory Committee on Human Research Protections (SACHRP). Nominations will close March 16, 2012.

SACHRP provides advice and recommendations to the Secretary of the Department of Health and Human Services (HHS) and the Assistant Secretary forprotections for human subjects in research. Additional details and instructions for Health of HHS on matters pertaining to the continuance and improvement of functions within the authority of HHS directed toward submitting nominations are included in the Federal Register notice which can be accessed here or in PDF format here.

* GOVERNOR DECLARES STATE OF EMERGENCY IN WASHINGTON *

http://www.kirotv.com/news/news/governor-declares-state-emergency-washington/nGTqM/

Cindy Gates, Vice President of Education & Consulting Services at WIRB has been invited to speak

on “Recent Developments in Human Subjects Protection Regulation” at MAGI’s Clinical Research Conference – 2012 East in Washington, DC, May 20-23, 2012 and at HCCAs Research Compliance Conference on “Recent Developments in Clinical Trial Regulation and Oversight” in Austin, Texas June 3-6, 2012.

New federal requirement for consent 21 CFR 50.25(c)

Effective March 7, 2012, a new federal requirement for consent forms takes effect. New federal regulation 21 CFR 50.25(c) states:

“When seeking informed consent for applicable clinical trials, as defined in 42 U.S.C. 282(j)(1)(A), the following statement shall be provided to each clinical trial subject in informed consent documents and processes. This will notify the clinical trial subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank under paragraph (j) of section 402 of the Public Health Service Act. The statement is: "A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time."

Because not all research reviewed by WIRB will need to have the statement referenced above in consent forms, we are in the process of updating our initial review submission forms with the following new question:

Is this research an “applicable clinical trial” that must be registered on ClinicalTrials.gov? yes no

If yes, effective March 7, 2012, the consent form must include the following statement (verbatim)

"A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time."

For more information see Federal Register: January 4, 2011 (Volume 76, Number 2) Page 256-270

When the question is answered “yes,” WIRB will include the required statement in the consent form if it is not already there.

If the question is answered “no”, WIRB will not include the required statement, but will not remove it when it is in the submitted consent forms.

WIRB encourages submitters to use our online “smart form” to submit new research, but if you prefer to download and complete the Word or PDF forms posted on our web site, please be sure to use the current version (which is labeled “2012” in the footer). WIRB cannot accept the older versions of the form after February 29, 2012.

Existing approved consent forms will not be modified to include the statement unless WIRB receives a request to add it.

WIRB's Chief Compliance Officer Spoke at the 11th Forum for Ethical Review Committees in Asia and the Western Pacific (FERCAP)

WIRB’s Chief Compliance Officer, David Forster, JD, recently attended and spoke at the 11th Forum for Ethical Review Committees in Asia and the Western Pacific (FERCAP) hosted by the Daegu Catholic University Medical Center (DCUMC) held in Daegu, South Korea on November 21st and 22nd, 2011. Mr. Forster gave a presentation on “Possible Changes to the United States IRB Regulations” regarding the Health and Human Services Advance Noticed of Proposed Rulemaking (ANPRM) for Revisions to the Common Rule.

Some of the goals of this year’s FERCAP meeting were to describe innovative concepts, practices and initiatives related to the ethical conduct of research, identify good ethical practices in innovative and integrative health research and to develop models of good ethical review practices and procedures within the context of diverse Asian research environments.

WIRB is honored and proud to continue our ongoing relationship with FERCAP and DCUMC, and to continue participation in capacity building in ethical review in all parts of the world.

WIRB Executives spoke at the First Academic Conference of the Committee of Ethics Review of WFCMS

WIRB Executives recently attended and spoke at the First Academic Conference of the Committee of Ethics Review of WFCMS (World Federation of Chinese Medicine Societies), held in Nanjing, China on November 19th and 20th, 2011. John F. Ennever, MD, gave two presentations: “Challenges for the ERC: Assessment of study design, risk and benefits in clinical trials” and “Protecting the vulnerable: Special ethical requirements for research involving children.” Fanny K. Ennever, PhD, gave one presentation: “Informed consent in clinical trials involving Traditional Chinese Medicine: Evaluating the descriptions of research procedures and alternatives.” John Ennever was elected a Vice Chair of the Committee of Ethics Review, and Hsiang-Ning Luk, MD and Bradley Waite, DO, from WIRB were elected as Special Members of the Committee of Ethics Review. WIRB is grateful for the opportunity to assist in the development of laws, regulations and SOPs governing the review of clinical trials involving Traditional Chinese Medicine such as herbs and acupuncture.

OHRP link to announce notice of proposed rule making

The U.S. Department of Health and Human Services has announced that the federal government is contemplating various ways of enhancing the regulations overseeing research on human subjects. Before making changes to the regulations the government is seeking the public’s input on an array of issues related to the ethics, safety, and oversight of human research. WIRB encourages all parties involved in the conduct of research to become familiar this proposal and to submit comments to HHS.

http://www.hhs.gov/ohrp/humansubjects/anprm2011page.html

Changes to Planned Protocol Deviation Review Policy (November 2010)

Due to differing regulatory requirements, WIRB reporting requirements for planned protocol deviations differ depending on whether your research is federally funded or is covered by a federal-wide assurance (FWA):

If the research is not federally funded and the research is not conducted under an FWA, planned protocol deviations that may adversely affect the rights, safety or welfare of subjects or the integrity of the research data should be submitted to WIRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects [ (DHHS 45 CFR § 46.103(b)(4); (FDA 21 CFR § 56.108(a)(4); ICH 3.3.7].
If the research is federally funded or is conducted under an FWA, all planned protocol deviations must be submitted to WIRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects [ (DHHS 45 CFR § 46.103(b)(4); (FDA 21 CFR § 56.108(a)(4); ICH 3.3.7].

The reason for these different requirements regarding planned protocol deviations is that the Office for Human Research Protections (OHRP) has adopted the regulatory interpretation that every planned protocol deviation is a change in research that needs prior IRB review and approval before implementation. However, the Food and Drug Administration (FDA) has not adopted this interpretation.

Use the WIRB Change in Research and Subject Recruitment (Ads) Submission Form to request approval of a planned protocol deviation prior to implementation. (Deviations necessary to eliminate apparent immediate hazards to the human subjects should be reported within 10 days on the Report Form for Unanticipated Problems that are Not Adverse Events.)

These instructions are provided on the back of the Certificate of Approval and in the Report Form for Unanticipated Problems that are Not Adverse Events.

WIRB announces two international events to help increase ethical awareness in medical and human research around the world.

WIRB, together with Daegu Catholic University Medical Center (DCUMC), had hosted an IRB Summit 2011, April 21–23, in Daegu, Korea. With projected attendance of more than 800 researchers, physicians, and health care professionals, IRB Summit 2011 provided balanced perspectives on ethical, clinical, and state-of-the-art research today, as well as the latest trends worldwide. A meeting of WIRB’s International Fellows Association also took place during the Summit.

This spring, in addition to delivering on-site training around the U.S., WIRB had presented a customized two-day course on human subject protection, gene transfer, and stem cell topics to the Supreme Council of Health in Doha, Qatar.

2013 AAHRPP Conference

WIRB-Copernicus Group Thought Leaders Tapped for Key Roles at 2013 AAHRPP Conference in Miami Florida on April 3-5, 2013. Read the press release for more information.

Events

June 3-7, American Society of Clinical Oncology Annual Meeting
WIRB had hosted a booth at ASCO in Chicago, June 3 to June 7. Find more information about the event at: http://chicago2011.asco.org
June 12-14, NIH OBA/Eagleson Institute Conference: IBCs in an Evolving Research Landscape
WIRB’s had hosted a booth at this conference in San Diego, June 12 through June 14. Learn more about this event. http://www.eagleson.org/index.php?option=com_content&view=article&id=95:nih-conference&catid=13:seminars&Itemid=78
June 19-23, Drug Information Association Conference
We will also have a booth at the DIA conference in Chicago, June 19 through June 23. Find more information about the event at: www.diahome.org
Oct 27-Nov 2, American Biological Safety Association 54th Annual Conference
IBC Services will be exhibiting at the 2011 ABSA meetings in Anaheim, October 27 through November 2. For more information, visit http://www.absaconference.org
November 21, Canadian Association of Research Ethics Board
Canadian Association of Research Ethics Board (CAREB) in Niagara Falls, Ontario, Canada
Dec 2-4, PRIM&R 2011 Advancing Ethical Research Conference
WIRB is a Silver Supporter for the PRIM&R 2011 Advancing Ethical Research Conference in National Harbor, MD. Stop by the WIRB Exhibit at spaces 205-207 in the Exhibit Hall.
March 12-17, ASCPT 2012 Annual Meeting
WIRB will be attending the ASCPT 2012 Annual Meeting in National Harbor, MD. For more information, visit www.ascpt.org.
April 14-17, ACRP 2012 Global Conference & Exhibition
WIRB will be a GOLD Sponsor this year at the ACRP 2012 Global Conference & Exhibition in Houston, TX. Visit WIRB at Booth #700 & 702. For more information, visit www.acrp2012.org.
April 18-20, 2012 AAHRPP Conference: Quality Human Research Protection Programs
WIRB will be attending the AAHRPP Conference in Denver, CO. For more information, visit www.aahrpp.org.
June 1-5, ASCO 2012 Annual Meeting
WIRB will be an Exhibitor at the ASCO 2012 Annual Meeting in Chicago, IL. Visit WIRB at Booth #11147. For more information, visit www.chicago2012.asco.org.
June 22, OHRP 2012 Community Forum
WIRB will be an Exhibitor at the OHRP 2012 Community Forum at UPMC in Pittsburgh, PA.
June 24-28 DIA 2012 Annual Meeting
WIRB will be an Exhibitor at the DIA 2012 Annual Meeting in Philadelphia, PA. Visit WIRB at Booth #2107. For more information, visit www.diahome.org.
October 21-24, 2012 WIRB exhibit booth at Magi’s Clinical Research
Visit the WIRB exhibit booth at Magi’s Clinical Research Conference - 2012 West in San Diego, California, October 21-24, 2012. For more information, visit www.iibig.com.
December 4-6, 2012 WIRB exhibit booth at PRIM&R
Visit the WIRB exhibit booth at PRIM&R Advancing Ethical Research Conference in San Diego, California, December 4-6, 2012. For more information, visit, www.primr.org.

News

The WIRB-Copernicus Group Partners with Mytrus, Inc. to Deliver Revolutionary, Interactive Electronic Informed Consent Solution

CWWeekly’s semi-monthly company profile feature

New Streamlined Policy for Unexpected Consent Translations Needs

March 2013 Documentation Changes

2013 Fee Schedule Changes and Improvement Updates

MAGI Clinical Research Conference - 2013 East

CenterWatch Clinical Research Conference – 2013 East

ASCO Annual Meeting

DIA 49th Annual Meeting

Oct. 4-5th, Seattle Waterfront - 2012 WIRB Annual Knowledge Summit

Eight WIRB staff had the pleasure of attending the Drug Information Association (DIA) 2012 Annual Meeting in Philadelphia June 25-28, 2012

On March 4, 2012, Dateline NBC aired a story regarding the submission of a fake clinical protocol to three independent IRBs as part of a sting operation.

Arsenal Capital Partners and Western Institutional Review Board (WIRB) Announce the Acquisition of WIRB and the Appointment of Leading Clinical Research Experts as Advisors

The Office for Human Research Protections (OHRP) is seeking nominations of qualified candidates for appointment to the Secretary’s Advisory Committee on Human Research Protections (SACHRP). Nominations will close March 16, 2012.

*** GOVERNOR DECLARES STATE OF EMERGENCY IN WASHINGTON ***

Cindy Gates, Vice President of Education & Consulting Services at WIRB has been invited to speak

New federal requirement for consent 21 CFR 50.25(c)

WIRB's Chief Compliance Officer Spoke at the 11th Forum for Ethical Review Committees in Asia and the Western Pacific (FERCAP)

WIRB Executives spoke at the First Academic Conference of the Committee of Ethics Review of WFCMS

OHRP link to announce notice of proposed rule making

Changes to Planned Protocol Deviation Review Policy (November 2010)

WIRB announces two international events to help increase ethical awareness in medical and human research around the world.

2013 AAHRPP Conference

Events

June 3-7, American Society of Clinical Oncology Annual Meeting

June 12-14, NIH OBA/Eagleson Institute Conference: IBCs in an Evolving Research Landscape

June 19-23, Drug Information Association Conference

Oct 27-Nov 2, American Biological Safety Association 54th Annual Conference

November 21, Canadian Association of Research Ethics Board

Dec 2-4, PRIM&R 2011 Advancing Ethical Research Conference

March 12-17, ASCPT 2012 Annual Meeting

April 14-17, ACRP 2012 Global Conference & Exhibition

April 18-20, 2012 AAHRPP Conference: Quality Human Research Protection Programs

June 1-5, ASCO 2012 Annual Meeting

June 22, OHRP 2012 Community Forum

June 24-28 DIA 2012 Annual Meeting

October 21-24, 2012 WIRB exhibit booth at Magi’s Clinical Research

December 4-6, 2012 WIRB exhibit booth at PRIM&R

* GOVERNOR DECLARES STATE OF EMERGENCY IN WASHINGTON *